Sign In
Buy MESO
$14.17
-0.380 (-2.61%)
At Close: Jul 31, 2026
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
06:27pm, Wednesday, 11'th Feb 2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided data presented at the Feb
Mesoblast: Real-World Data Validates The Bull Case For Ryoncil
05:59am, Wednesday, 11'th Feb 2026
Mesoblast (MESO) is demonstrating rapid revenue growth post-Ryoncil launch, with Q4 gross sales up 60% sequentially and strong market penetration. MESO's balance sheet is fortified by $130M cash and a
Mesoblast (NASDAQ:MESO) Share Price Passes Below 50-Day Moving Average – Time to Sell?
04:38am, Saturday, 07'th Feb 2026
Shares of Mesoblast Limited (NASDAQ: MESO - Get Free Report) passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $18.19 and traded as low as $15.5
Ryoncil® Net Revenues Increase for the Quarter to US$30M
06:54pm, Wednesday, 28'th Jan 2026
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryonc
NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from th
Mesoblast reports $US35.1m in gross revenue from sales of its cell therapy Ryoncil
05:14am, Friday, 09'th Jan 2026
Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) reported $US35.1 million ($52.4 million) in gross revenue from Ryoncil sales in the December quarter, up 60% on the...
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
06:46pm, Thursday, 08'th Jan 2026
Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility
Financial Survey: Alterity Therapeutics (NASDAQ:ATHE) and Mesoblast (NASDAQ:MESO)
01:08am, Friday, 02'nd Jan 2026
Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companie
Mesoblast Announces Changes to Board of Directors' Leadership Roles
06:02pm, Thursday, 01'st Jan 2026
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
06:57pm, Monday, 29'th Dec 2025
Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWI
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer
Mesoblast Participation at Piper Sandler Conference
06:10pm, Wednesday, 03'rd Dec 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
06:39pm, Monday, 24'th Nov 2025
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, togethe
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate
